{"id":745,"date":"2026-01-05T05:35:00","date_gmt":"2026-01-05T13:35:00","guid":{"rendered":"https:\/\/getasecondopinion.ai\/blog\/?p=745"},"modified":"2026-01-04T15:36:33","modified_gmt":"2026-01-04T23:36:33","slug":"lynkuet-new-non-hormonal-option-for-menopausal-hot-flashes","status":"publish","type":"post","link":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/lynkuet-new-non-hormonal-option-for-menopausal-hot-flashes\/","title":{"rendered":"LYNKUET: New Non\u2011Hormonal Option for Menopausal Hot Flashes"},"content":{"rendered":"\n

Hot flashes are one of the most disruptive symptoms of menopause, affecting sleep, mood, work, and overall quality of life. For decades, hormone therapy has been the most effective treatment – but it isn\u2019t right for everyone. That\u2019s why the FDA\u2019s approval of LYNKUET<\/a> (elinzanetant) in late 2025 has generated so much interest. It\u2019s a non\u2011hormonal, once\u2011daily medication designed specifically to reduce moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes.<\/p>\n\n\n\n

If you\u2019re exploring treatment options or simply trying to understand what this new medication offers, we\u2019ll break down the science, clinical trials, safety considerations, and what patients should keep in mind when discussing LYNKUET<\/a> with their healthcare provider.<\/p>\n\n\n\n

What LYNKUET Is – and Why It Matters<\/strong><\/h2>\n\n\n\n

LYNKUET<\/a> is the first medication of its kind to target the neurokinin pathways in the brain that regulate body temperature. During menopause, declining estrogen levels cause certain neurons – called KNDy neurons – to become overactive. This overactivity disrupts the body\u2019s internal thermostat, triggering sudden waves of heat, sweating, and flushing.<\/p>\n\n\n\n

Instead of replacing estrogen, LYNKUET<\/a> works by blocking two key receptors on these neurons: NK1 and NK3. By calming this overactive signaling, the medication helps restore temperature stability. For people who cannot or prefer not to take hormone therapy, this offers a meaningful new option.<\/p>\n\n\n\n

LYNKUET<\/a> is taken once daily at bedtime, with or without food. The recommended dose is 120 mg, delivered as two 60 mg capsules that must be swallowed whole.<\/p>\n\n\n\n

\n
\n
\n

Better Treatment, Lower Cost – No Catch.<\/h3>\n\n\n\n

Find safer, more effective medications with fewer side effects – often for less money. It\u2019s fast, free, and personalized. Learn More \u2192<\/a><\/strong><\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n

How LYNKUET Was Studied<\/strong><\/h2>\n\n\n\n

The FDA approval was based on data from the OASIS clinical trial program, which included three large, well\u2011designed studies: OASIS\u20111, OASIS\u20112, and OASIS\u20113. Together, these trials enrolled more than 1,420 women across 21 countries, including the United States, Canada, and several European nations.<\/p>\n\n\n\n

All participants were experiencing moderate to severe hot flashes, and the studies were randomized, double\u2011blind, and placebo\u2011controlled – the gold standard for evaluating new medications.<\/p>\n\n\n\n

The first two trials focused on how well LYNKUET<\/a> reduced the frequency and severity of hot flashes over the first 12 weeks. The third trial followed participants longer to assess safety and durability of benefit.<\/p>\n\n\n\n

Across all three studies, the results were consistent: LYNKUET<\/a> significantly reduced both the number and intensity of hot flashes compared to placebo. Many participants saw improvements as early as Week 4, with continued progress through Week 12 and beyond. Importantly, the benefits were similar across different ages, races, and geographic regions, suggesting the medication works broadly across diverse populations.<\/p>\n\n\n\n

What Patients Should Know About Safety<\/strong><\/h2>\n\n\n\n

Like all medications, LYNKUET<\/a> comes with potential side effects and safety considerations. Most are mild, but some require monitoring or special precautions.<\/p>\n\n\n\n

Common Side Effects<\/strong><\/h3>\n\n\n\n

The most frequently reported side effects in clinical trials included:<\/p>\n\n\n\n